Gedatolisib (BioDeep_00000182498)

   

human metabolite blood metabolite


代谢物信息卡片


1-{4-[4,6-bis(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}urea

化学式: C32H41N9O4 (615.3281346)
中文名称: 吉达利塞
谱图信息: 最多检出来源 Homo sapiens(blood) 15.19%

分子结构信息

SMILES: CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1
InChI: InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)

描述信息

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively[1]. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2[2].
Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively[1]. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2[2].

同义名列表

8 个代谢物同义名

1-{4-[4,6-bis(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}urea; 1-(4-((4-(dimethylamino)Piperidin-1-yl)carbonyl)phenyl)-3-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea; Gedatolisib (PF-05212384, PKI-587); PKI-587gedatolisib; Gedatolisib; PKI 587; PKI-587; PF-05212384



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Ying Wang, Judith F Smith, Marcela M Araya, Kai-Hsin Ken Liao, Boris Gorovits. Development of a Highly Specific Anti-drug Antibody Assay in Support of a Nanoparticle-based Therapeutic. The AAPS journal. 2020 06; 22(4):81. doi: 10.1208/s12248-020-00462-z. [PMID: 32488626]
  • Wei Song, Joseph A Tweed, Ravi Visswanathan, James P Saunders, Zhenhua Gu, Christopher L Holliman. Bioanalysis of Targeted Nanoparticles in Monkey Plasma via LC-MS/MS. Analytical chemistry. 2019 11; 91(21):13874-13882. doi: 10.1021/acs.analchem.9b03367. [PMID: 31584812]
  • Brett E Houk, Christine W Alvey, Ravi Visswanathan, Leonid Kirkovsky, Kyle T Matschke, Emi Kimoto, Tim Ryder, R Scott Obach, Chandrasekar Durairaj. Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion. Clinical pharmacology in drug development. 2019 01; 8(1):22-31. doi: 10.1002/cpdd.615. [PMID: 30256541]
  • Juncal Aldaregia, Ainitze Odriozola, Ander Matheu, Idoia Garcia. Targeting mTOR as a Therapeutic Approach in Medulloblastoma. International journal of molecular sciences. 2018 Jun; 19(7):. doi: 10.3390/ijms19071838. [PMID: 29932116]
  • Hideki Makinoshima, Shigeki Umemura, Ayako Suzuki, Hiroki Nakanishi, Ami Maruyama, Hibiki Udagawa, Sachiyo Mimaki, Shingo Matsumoto, Seiji Niho, Genichiro Ishii, Masahiro Tsuboi, Atsushi Ochiai, Hiroyasu Esumi, Takehiko Sasaki, Koichi Goto, Katsuya Tsuchihara. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma. Cancer research. 2018 05; 78(9):2179-2190. doi: 10.1158/0008-5472.can-17-2109. [PMID: 29490947]
  • Zev A Wainberg, Maria Alsina, Heloisa P Soares, Irene Braña, Carolyn D Britten, Gianluca Del Conte, Patrick Ezeh, Brett Houk, Kenneth A Kern, Stephen Leong, Nuzhat Pathan, Kristen J Pierce, Lillian L Siu, Jennifer Vermette, Josep Tabernero. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Targeted oncology. 2017 Dec; 12(6):775-785. doi: 10.1007/s11523-017-0530-5. [PMID: 29067643]